97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

39 trials found

diseases per page:

Showing 1 to 10 of 39 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05702879 (ClinicalTrials.gov)	April 1, 2023	18/1/2023	Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy ...	An Early Combined Microbiota and Metabolic Signature in Ulcerative Colitis Patients Predict the Clin ...	Ulcerative Colitis	Drug: Ozanimod;Drug: TNF Inhibitor;Drug: Steroids;Drug: Vedolizumab;Drug: Ustekinumab	University Hospital Inselspital, Berne	Bristol-Myers Squibb	Not yet recruiting	18 Years	80 Years	All	240		NULL
2	NCT05369832 (ClinicalTrials.gov)	December 16, 2022	6/5/2022	An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice	A Phase 4, Prospective, Open-label Study of Ozanimodto Explore the Safety, Efficacy, Quality of Life ...	Colitis, Ulcerative	Drug: Ozanimod	Bristol-Myers Squibb	NULL	Recruiting	18 Years	N/A	All	415	Phase 4	United States;Puerto Rico
3	NCT05644665 (ClinicalTrials.gov)	December 9, 2022	1/12/2022	A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimodin Chinese Participants With Moder ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimodto Evalua ...	Ulcerative Colitis	Drug: Ozanimod;Drug: Placebo	Bristol-Myers Squibb	NULL	Recruiting	18 Years	75 Years	All	240	Phase 3	China;Taiwan
4	EUCTR2021-002308-11-ES (EUCTR)	21/07/2022	21/07/2022	A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacok ...	A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacok ...	Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code ...	Product Name: Ozanimod HCL Product Code: RPC1063 INN or Proposed INN: Ozanimod HCL Other descriptive name ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2;Phase 3	France;United States;Canada;Belgium;Poland;Spain;Russian Federation;Israel;Germany;Netherlands;Unite ...
5	JPRN-jRCT2021220013	01/07/2022	18/06/2022	A Study Investigating Oral Ozanimod(RPC1063) in Pediatric Participants With Moderate to Severe Activ ...	A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Ulcerative Colitis (UC)	Ozanimod High Dose Ozanimod Low Dose	Liu W. Jerry	NULL	Pending	>= 2age old	<= 17age old	Both	120	Phase 2-3	France;United States;Japan
6	NCT05076175 (ClinicalTrials.gov)	May 30, 2022	4/10/2021	A Study Investigating Oral Ozanimod(RPC1063) in Pediatric Participants With Moderate to Severe Activ ...	A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Colitis, Ulcerative	Drug: Ozanimod	Bristol-Myers Squibb	NULL	Recruiting	2 Years	17 Years	All	120	Phase 2/Phase 3	United States;Belgium;France;Germany;Israel;Japan;Poland;Russian Federation;Spain;United Kingdom
7	NCT03915769 (ClinicalTrials.gov)	June 3, 2019	12/4/2019	To Evaluate Efficacy and Long-term Safety of Ozanimodin Japanese Subjects With Moderately to Severel ...	A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimodto Eval ...	Colitis, Ulcerative	Drug: Ozanimod;Other: Placebo	Celgene	NULL	Active, not recruiting	18 Years	75 Years	All	195	Phase 3	Japan
8	EUCTR2015-001600-64-AT (EUCTR)	25/07/2018	17/04/2018	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: yes Male: yes	1200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
9	EUCTR2015-001600-64-GR (EUCTR)	23/07/2018	19/04/2018	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
10	EUCTR2015-000319-41-GR (EUCTR)	23/07/2018	18/04/2018	The purpose of this study is to determine whether RPC1063 is safe and effective in the treatment of ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induct ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting			Female: yes Male: yes	900	Phase 3	United States;Belarus;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;France;Australia ...

First Previous1 2 3 4Next Last